Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Alnylam Pharmaceuticals Stories

2012-08-15 10:23:36

LA JOLLA, Calif., Aug. 15, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a collaboration with Biogen Idec (NASDAQ: BIIB) to identify microRNAs as biomarkers for multiple sclerosis (MS). Under the transaction, Biogen Idec will make an investment in Regulus in addition to upfront and milestone payments. The key objective of the collaboration...

2012-08-14 10:24:54

LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets which are currently in pre-clinical development. These targets are focused on cardiovascular and metabolic diseases and...

2012-06-04 17:41:18

Pared-down nucleic acid nanoparticle poses less risk of side effects, offers better targeting. Using a technique known as “nucleic acid origami,” chemical engineers have built tiny particles made out of DNA and RNA that can deliver snippets of RNA directly to tumors, turning off genes expressed in cancer cells. To achieve this type of gene shutdown, known as RNA interference, many researchers have tried – with some success – to deliver RNA with particles made...

2012-04-30 02:25:29

LA JOLLA, Calif., April 30, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Bruce Carter, Ph.D. to its Board of Directors. Dr. Carter currently serves as an independent member of the Board of Directors of Immune Design Corp., a privately held biotech company located in Seattle, and as a board member of additional scientific organizations. He...

2012-04-23 02:27:58

LA JOLLA, Calif., April 23, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the Japan Patent Office has issued a Decision to Grant a Patent in the 'Sarnow' patent series for microRNA-122 (miR-122) therapy in the treatment of chronic hepatitis C virus (HCV) infection. The Sarnow patent estate, owned by Stanford University and exclusively licensed to Regulus, has...

2012-03-20 22:20:51

LONDON, March 21, 2012 /PRNewswire/ -- Silence Therapeutics Plc [http://silence-therapeutics.com ] (AIM: SLN), a leading international RNAi therapeutics company [http://silence-therapeutics.com/pipeline/clinical-programs/#!/about-us ], today announces its unaudited preliminary results for the year ended 31 December 2011. HIGHLIGHTS - Impressive interim data from Phase I trials of Atu027 (lead programme in metastatic cancer) presented at the...

2012-02-16 07:00:00

LA JOLLA, Calif., Feb. 16, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data investigating the role of microRNA-21 (miR-21) in the treatment of kidney fibrosis has been published in the journal Science Translational Medicine. Regulus' lead program for fibrosis targets miR-21, which is up-regulated in fibrotic tissues of humans. Previous...

2012-01-05 07:00:00

LA JOLLA, Calif., Jan. 5, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data from its proprietary lead program targeting microRNA-33a/b (miR-33a/b), currently in preclinical development for the treatment of atherosclerosis, will be presented at the Keystone Symposium "Nucleic Acid Therapeutics: From Base Pairs to Bedsides" held Jan. 10-15, 2012, in...

2011-11-08 07:00:00

LA JOLLA, Calif., Nov. 8, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced presentations on its preclinical programs for the treatment of fibrosis at the American Association of Nephrology "Kidney Week" Annual Meeting held Nov. 8-13, 2011, in Philadelphia. New data will be presented demonstrating that microRNA-21 (miR-21) is upregulated in human patients and animal...

2011-11-02 07:00:00

LA JOLLA, Calif., Nov. 2, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the Australian Patent Office has recently granted claims in the 'Sarnow' patent series for microRNA-122 (miR-122) therapy in the treatment of hepatitis C viral (HCV) infections. The granted claims in Australia extend the reach of the Sarnow patent estate that already covers the use of...